Home > Haematology > ASH 2021 > Lymphoma > Axi-cel more effective but tisa-cel less toxic in DLBCL

Axi-cel more effective but tisa-cel less toxic in DLBCL

Presented By
Dr Emmanuel Bachy, Hospices Civils de Lyon, France

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2021
In a matched set population of patients with diffuse large B-cell lymphoma (DLBCL) who had received ≥2 lines of treatment, axicabtagene ciloleucel (axi-cel) resulted in a significantly prolonged progression-free survival (PFS) compared with tisagenlecleucel (tisa-cel). However, axi-cel was associated with significantly more frequent grade ≥3 neurotoxicity compared with tisa-cel. These results could help refine specific patient sub-populations who benefit most from each type of CAR T-cell therapy. Axi-cel and tisa-cel are autologous anti-CD19 CAR T-cell therapies approved in the US and EU for adults with relapsed/refractory (R/R) DLBCL after ≥2 lines of systemic therapy. Dr Emmanuel Bachy (Hospices Civils de Lyon, France) and others conducted a propensity score-matched comparison of axi-cel and tisa-cel in a large cohort of R/R DLBCL patients treated outside of clinical trials. After a 1:1 ratio propensity score-matching, therapy outcomes were compared betw...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on